AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
ALX Oncology Holdings Q3 2025 Earnings Call Transcript: Evorpacept Data Validates CD47 Biomarker in HER2-Positive Gastric Cancer, ALX2004 ADC Enters Clinic
ByAinvest
Friday, Nov 7, 2025 3:58 pm ET1min read
ALX Oncology Holdings Inc. reported Q3 2025 earnings and highlighted key accomplishments, including data from the ASPEN-06 trial that showed CD47 expression as a predictive biomarker for increased durable clinical response with evorpacept in HER2-positive gastric cancer patients. The company also discussed its development strategy for evorpacept and its novel ALX2004 EGFR-targeted ADC, which is now in the clinic.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet